The economic burden of inflammatory bowel disease: Clear problem, unclear solution

Digestive Diseases and Sciences

Volumn 57, Issue 12, 2012, Pages 3042-3044

  Stone, Christian D ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST CONTROL; COST OF ILLNESS; CROHN DISEASE; DISEASE SEVERITY; DRUG COST; ENTERITIS; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITAL COST; HUMAN; MEDICAL FEE; OUTPATIENT CARE; PRIORITY JOURNAL; REMISSION; REVIEW; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE;

EID: 84871626246     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2417-8     Document Type: Review

References (12)

1. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA. Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from United States National Survey. Dig Dis Sci. 2012 (Epub ahead of print). doi: 10.1007/s10620-012-2289-y
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-1429.
3. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511.
5. Everhart JE, editor. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2008; NIH Publication No. 09-6443.
6. Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008;14:6641-6647.
7. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603-1609.
8. Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7:103-109.
9. Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther. 2007;26:1313-1323.
10. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterol. 2005;128:862-869.
11. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135:1493-1499.
12. IBD Standards Group. Quality Care: Service Standards for the healthcare of people who have Inflammatory Bowel Disease (IBD). Oyster Healthcare Communications Ltd, 2009.